|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thrombophilic profile (factor V G1691A (Leiden), factor V H1299R (R2), prothrombin G20210A, MTHFR C677T, MTHFR A1298C, factor XIII V34L, β-fibrinogen-455 G-A and plasminogen activator inhibitor (PAI)-1 4G/5G) was evaluated using the cardiovascular diseases (CVD) StripAssay based on DNA isolation, PCR and reverse hybridisation.
|
31300468 |
2019 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Two genes of the CVD panel demonstrated a strong relationship with RPL, including, MTHFR (C677T homozygosity, A1298C homozygosity, and compound heterozygosity for C677T and A1298C) and Factor II (heterozygosity for G20210A).
|
29974397 |
2018 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of nine gene variants/polymorphisms - F5 (Leiden - R5 06Q, rs6025), F2 (20210G > A, rs1799963), F13A1 (V34L, rs5985), MTHFR (677C > T - A222V, rs1801133), MTHFR (1298A > C - E429A, rs1801131), FGB (-455G > A -c.-463G > A; rs1800790), SERPINE1 (PAI14G/5G - rs1799889), ACE (ACE I/D, rs1799752), ITGB3 (GPIIIa L33P, rs5918) and the APOE E2/E3/E4 alleles (rs7412, rs429358) - were genotyped in 200 newly diagnosed ischemic stroke (IS) patients, 165 patients with ischemic coronary heart disease (CHD) and 159 controls with no cerebroor cardiovascular disease (non-CVD).
|
27629735 |
2016 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutation analyses were conducted using the real-time polymerase chain reaction method to screen six common mutations (Factor V G1691A, PT G20210A, Factor XIII V34L, MTHFR A1298C and C677T and PAI-1 -675 4G/5G) found in CVD panel.
|
24532105 |
2014 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In addition, the 1298A>C variant was significantly associated with CVD (OR = 3.32; P = 0.030).
|
21270364 |
2011 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
|
18622257 |
2008 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, A1298C polymorphism of MTHFR gene appears to be associated with the severity of carotid atherosclerosis and co-occurrence of MTHFR polymorphisms may be a risk factor for CVD in patients on hemodialysis.
|
17899317 |
2008 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated total homocysteine (tHcy) concentrations and relations between tHcy and folate, cobalamin (Cbl), genetic polymorphisms (MTHFR 677C > T, MTHFR 1298A > C, MTHFR 1793G > A), blood pressure (BP), body mass index (BMI), cholesterol, triglycerides, sports activities, family and individual history of cardiovascular disease (CVD) and lifestyle issues in 264 healthy children and adolescents (2-17 y).
|
17065574 |
2006 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutant alleles with the 677C-->T and 1298A-->C polymorphisms of the MTHFR gene, and consequent lower methylentetrahydrofolate reductase enzyme activity, have been related to higher plasma homocysteine levels, which are associated with cardiovascular diseases.
|
12356947 |
2002 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Hyperhomocysteinemia, serum folate levels and both C677T and A1298C MTHFR mutations are associated with CVD in HD patients.
|
12187094 |
2002 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Since homocysteine itself is considered to be positively associated with the risk of CVD, these findings indicate that the 1298A-->C mutation cannot be considered a major risk factor for CVD.
|
11692165 |
2001 |
|
rs397507444
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Particular emphasis has been given to the role of two common polymorphisms (MTHFR 677C-->T, 1298A-->C) in cardiovascular disease, cerebrovascular disease, venous thrombosis, longevity, neural tube defects, pregnancy/preeclampsia, diabetes, cancer, psychiatry, renal failure and renal replacement therapy.
|
10720211 |
2000 |